在政策引导与市场需求的双重驱动下，中国医药行业正经历新一轮深度整合。近日，中国医药集团有限公司（以下简称“国药集团”）先后宣布收购血制品上市公司派斯双林生物制药股份有限公司（以下简称“派林生物”）和药用玻璃上市公司山东省药用玻璃股份有限公司（以下简称“山东药玻”），成为近期医药行业并购的典型案例。国资央企成为并购市场的主力军，其雄厚的资金实力和卓越的资源整合能力显著改变了行业竞争格局。以中国医药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.